Disease: Von Willebrand Disease (VWD)

Patient(s): Found in 2 families

Variant: VWF NM_000552.5: c.2311A>G, p.(M771V Homozygous variant in exon 18 (VWF D' domain; 8 residues down from proteolytic VWFpp furin cleavage site)

Family: In family 1 there are 4 homozygous patients (2 male and 2 female), and one heterozygous patient (1 female). The affected females are denoted as person 1 and person 4 and the affected males are person 2 and person 3. There are three WT family members (1 female and 2 male), grandparents of these members are of unknown genotype including a daughter of an affected female and a WT male. Note here that in the family a p.R2663P variant has co-segregated with the above-mentioned variant but is not suspected to be the pathogenic driver of resulting bleeding tendency.

In family 2 the parents of the homozygous affected male are of unknown genotype. The affected male is denoted as person 7.

Phenotypes: Person 1- nose bleed, skin bleed, GI bleeding, oral cavity bleeds, Menorrhagia, muscle bleeding, and joint bleeding. Receives on-demand treatment for bleeding.

Person 2-Nose bleed, skin bleed, bleeding from small wounds, oral cavity bleeds, bleeding after tooth extraction, joint bleeding. Received prophylactic treatment, reduced to on-demand treatment after a few years.

Person 3-Nose bleed, skin bleed, oral cavity bleeds, bleeding after tooth extraction, muscle bleeding. Receives on-demand treatment for bleeding phenotype.

Person 4- Nose bleed, bleeding from small wounds, oral cavity bleed, bleeding after tooth extraction, joint bleeding. Received prophylactic treatment that was increased after her menarche.

Person 7- Nose bleed, oral cavity bleeds, bleeding after surgery or trauma, joint bleeding. Previously on prophylaxis, now managing bleeding with on-demand treatment.

Note that both the p.R2663P co-segregated variant and p.M771V variant are reported in NCBI dbSNP database but functional effect not yet established.

NGS confirmed the genotype of all study participants.

for - key insight - severe limits of philanthropy - abiding by neoliberal logic severely constrains them - Post Capitalist Philanthropy Webinar 1 - Alnoor Ladha - Lynn Murphy - 2023

Willis, O. (2021, October 19). The pandemic won’t end with a bang, but more likely a fizzle. Here’s how. ABC News. https://www.abc.net.au/news/health/2021-10-20/covid-19-pandemic-when-does-it-end-become-endemic-like-flu/100549816

Pearson, C. (2021, September 27). New Study Finds A Huge Perk Of Getting Vaccinated After Having COVID-19. HuffPost UK. https://www.huffpost.com/entry/study-covid-vaccine_l_6151dbbde4b098483a792e18

https://twitter.com/GYamey/status/1453132196416524292?s=20&t=REKS2qu5Ti7lby2jmu6Imw

Beaumont, P. (2021, December 17). T-cells in Pfizer Covid jab recipients stay robust against severe illness. The Guardian. https://www.theguardian.com/world/2021/dec/17/t-cells-pfizer-covid-jab-robust-against-severe-illness-south-africa-research

Bar-On, Y. M., Goldberg, Y., Mandel, M., Bodenheimer, O., Freedman, L., Alroy-Preis, S., Ash, N., Huppert, A., & Milo, R. (2021). Protection Across Age Groups of BNT162b2 Vaccine Booster against Covid-19 (p. 2021.10.07.21264626). https://doi.org/10.1101/2021.10.07.21264626

Marsh, S. (2021, December 1). Severe Covid infection doubles chances of dying in following year, study finds. The Guardian. https://www.theguardian.com/world/2021/dec/01/severe-covid-infection-doubles-chances-of-dying-in-following-year-study

Covid-19: Efficacité vaccinale. (2021, October 11). EPI-PHARE. https://www.epi-phare.fr/rapports-detudes-et-publications/impact-vaccination-covid-octobre-2021/

Morris, J. (2021, August 17). Israeli data: How can efficacy vs. severe disease be strong when 60% of hospitalized are vaccinated? Covid Data Science. https://www.covid-datascience.com/post/israeli-data-how-can-efficacy-vs-severe-disease-be-strong-when-60-of-hospitalized-are-vaccinated

Carl T. Bergstrom. (2021, August 18). 1. There has been lots of talk about recent data from Israel that seem to suggest a decline in vaccine efficacy against severe disease due to Delta, waning protection, or both. This may have even been a motivation for Biden’s announcement that the US would be adopting boosters. [Tweet]. @CT_Bergstrom. https://twitter.com/CT_Bergstrom/status/1427767356600688646

Lehnen, N., Glasauer, S., Schröder, L., Regnath, F., Biersack, K., Bergh, O. V. den, & Werder, D. von. (2022). Post-COVID symptoms in the absence of organic deficit—Lessons from diseases we know. PsyArXiv. https://doi.org/10.31234/osf.io/yqar2

Yonker, L. M., Boucau, J., Regan, J., Choudhary, M. C., Burns, M. D., Young, N., Farkas, E. J., Davis, J. P., Moschovis, P. P., Bernard Kinane, T., Fasano, A., Neilan, A. M., Li, J. Z., & Barczak, A. K. (2021). Virologic Features of Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Children. The Journal of Infectious Diseases, 224(11), 1821–1829. https://doi.org/10.1093/infdis/jiab509

Magee, L. A., Dadelszen, P. von, Kalafat, E., Duncan, E. L., O’Brien, P., Morris, E., Heath, P., & Khalil, A. (2021). COVID-19 vaccination in pregnancy—Number needed to vaccinate to avoid harm. The Lancet Infectious Diseases, 0(0). https://doi.org/10.1016/S1473-3099(21)00691-5

Aufrichtig, A., & Walker, A. S. (2021, October 28). Who Had Covid-19 Vaccine Breakthrough Cases? The New York Times. https://www.nytimes.com/interactive/2021/10/28/us/covid-breakthrough-cases.html

ICMR drops Ivermectin, Hydroxychloroquine drugs from Covid treatment. (2021, September 24). The Times of India. https://timesofindia.indiatimes.com/india/icmr-drops-ivermectin-hydroxychloroquine-drugs-from-covid-treatment/articleshow/86475906.cms?__twitter_impression=true

Study finds no increased risk of COVID-19 vaccination in pregnancy. (n.d.). Retrieved October 4, 2021, from https://www.gavi.org/vaccineswork/study-finds-no-increased-risk-covid-19-vaccination-pregnancy

Mahase, E. (2021). Covid-19: Booster dose reduces infections and severe illness in over 60s, Israeli study reports. BMJ, 374, n2297. https://doi.org/10.1136/bmj.n2297

Kozlov, Max. ‘COVID-Vaccine Booster Shot Shows Promise in Israeli Study’. Nature, 16 September 2021. https://doi.org/10.1038/d41586-021-02516-4.

The BMJ. ‘Does the FDA Think These Data Justify the First Full Approval of a Covid-19 Vaccine?’, 23 August 2021. https://blogs.bmj.com/bmj/2021/08/23/does-the-fda-think-these-data-justify-the-first-full-approval-of-a-covid-19-vaccine/.

Carstensen, L. L., Shavit, Y. Z., & Barnes, J. T. (2020). Age Advantages in Emotional Experience Persist Even Under Threat From the COVID-19 Pandemic. Psychological Science, 31(11), 1374–1385. https://doi.org/10.1177/0956797620967261

Remmel, A. (2021). COVID vaccines and safety: What the research says. Nature, 590(7847), 538–540. https://doi.org/10.1038/d41586-021-00290-x

Garcia-Beltran et al showed that severely ill patients had the highest levels of antibodies. Anti-RBD IgG neutralisation was reduced in severely ill patients. The authors developed an antibody neutralisation potency index to indicate patients more likely to develop severe disease.

Garcia-Beltran WF, Lam EC, Astudillo MG, Yang D, Miller TE, Feldman J, et al. COVID-19-neutralizing antibodies predict disease severity and survival. Cell. 2021;184(2):476-88.e11.

MRC Centre for Global Infectious Disease Analysis on Twitter. (n.d.). Twitter. Retrieved 5 March 2021, from https://twitter.com/MRC_Outbreak/status/1331677485122121732

editor, Ian Sample Science. ‘Coronavirus: UK Scientists Identify Drugs That May Help Severe Cases’. The Guardian, 11 December 2020, sec. Science. https://www.theguardian.com/science/2020/dec/11/coronavirus-uk-scientists-identify-drugs-that-may-help-severe-cases.

Meeting the psychological needs of people recovering from severe coronavirus. (2020, May 7). https://www.youtube.com/watch?v=6hAUUTdhHlc&feature=youtu.be

Petersen, E., Koopmans, M., Go, U., Hamer, D. H., Petrosillo, N., Castelli, F., Storgaard, M., Khalili, S. A., & Simonsen, L. (2020). Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics. The Lancet Infectious Diseases, 0(0). https://doi.org/10.1016/S1473-3099(20)30484-9

Su, Q., Hu, J., Lin, H., Zhang, Z., Zhu, E. C., Zhang, C., Wang, D., Gao, Z., & Cao, B. (2020). Prevalence and risks of severe events for cancer patients with COVID-19 infection: A systematic review and meta-analysis. MedRxiv, 2020.06.23.20136200. https://doi.org/10.1101/2020.06.23.20136200